emtricitabine/tenofovir

DRUG8 trials

Sponsors

GlaxoSmithKline, French National Agency for Research on AIDS and Viral Hepatitis, HIV Prevention Trials Network, ViiV Healthcare, James Egan

Conditions

AIDSCOVID-19HIVHIV InfectionHIV InfectionsHIV-1HIV-I InfectionHuman Immunodeficiency Virus

Phase 1

Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers

CompletedNCT01276600

HIV Prevention Trials NetworkHIV

Start: 2011-01-31End: 2011-10-31Updated: 2025-03-25

Phase 2

Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia

CompletedNCT04359095

Universidad Nacional de ColombiaCOVID-19

Start: 2020-08-18End: 2021-06-30Updated: 2021-08-12

Phase 3

Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)

CompletedNCT00302822

French National Agency for Research on AIDS and Viral HepatitisAIDS, HIV Infections

Start: 2006-04-30End: 2009-12-31Updated: 2013-07-10

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

TerminatedNCT01345630

ViiV HealthcareHIV-1

Start: 2011-09-30End: 2014-01-31Updated: 2016-01-14

Phase 4

Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV

CompletedNCT00244712

GlaxoSmithKlineHIV Infection

Start: 2005-07-31End: 2008-04-30Updated: 2010-06-08

Immediate Initiation of Antiretroviral Therapy During Hyperacute HIV Infection

Active, not recruitingNCT02656511

University of California, San FranciscoHIV

Start: 2015-12-31End: 2028-05-31Target: 74Updated: 2025-06-15

Unknown Phase

Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV

CompletedNCT02495779

James EganHuman Immunodeficiency Virus

Start: 2015-07-31End: 2017-11-30Updated: 2019-03-27

Evaluation of Pre-Exposure Prophylaxis (PrEP) in Pregnant and Breastfeeding Women

CompletedNCT03902418

University of California, Los AngelesHIV-I Infection

Start: 2019-07-01End: 2024-09-30Updated: 2024-10-23

Related Papers

Autologous neutralizing antibody responses after antiretroviral therapy in acute and early HIV-1

Journal of Clinical Investigation2024-04-236 citations

Point-of-care testing for sexually transmitted infections and HIV pre-exposure prophylaxis among pregnant women in South Africa, 2021–2022: randomised controlled trial

Sexually Transmitted Infections2023-12-162 citations

Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial

BMJ2022-01-0779 citations

Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial.

2021-12-2028 citations

Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial.

2021-06-2747 citations

Antiretroviral reduction

AIDS2014-01-068 citations